China Resources Double-Crane announced that it has signed a repurchase agreement with Lantheus Medical Imaging, under which Lantheus will repurchase all rights in China to the octafluoropropane lipid microsphere injection for a total price of 30 million US dollars. As of the announcement date, the company has received the first installment of 15 million US dollars, equivalent to approximately 101 million yuan. The drug has not generated any market sales since obtaining the drug registration certificate, and this repurchase will not have a material impact on the company's current operating performance.
China Resources Double-Crane Pharmaceutical Co LtdLantheus repurchases China rights for $30M, but drug had no sales, so no material impact on performance.
Beijing Winsunny Pharmaceutical CO.LTD